Washington is currently home to 1729 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/14/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Small Cell Lung Cancer
Register for Updates
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
NCT06870487
Recruiting
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Fred Hutchinson Cancer Center., Seattle, Washington
Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Register for Updates
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785
Recruiting
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2025
Locations: MultiCare Research Institute for Research and Innovation, Tacoma, Washington
Conditions: Relapsing Multiple Sclerosis (RMS)
Register for Updates
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
Recruiting
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Clinical Study Site, Seattle, Washington
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT06856577
Recruiting
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an aver... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/14/2025
Locations: Adverum Clinical Site 131, Spokane, Washington
Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Register for Updates
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Research Site, Seattle, Washington
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969
Recruiting
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Overlake Arthritis and Osteoporosis Center, Bellevue, Washington
Conditions: Sjogrens Syndrome
Register for Updates
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076
Recruiting
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Vista Oncology, Olympia, Washington
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148
Recruiting
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/14/2025
Locations: Spokane Eye Clinical Research, Spokane, Washington
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Pa0016 50027, Seattle, Washington
Conditions: Psoriatic Arthritis
Register for Updates
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194
Recruiting
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will r... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/14/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Migraine
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Medstar Speciality Hospital, Northwest, Washington
Conditions: Colorectal Cancer
Register for Updates